Cover Image
市場調查報告書

醫藥品防止仿冒技術的全球市場

Pharmaceutical Anti-Counterfeiting Technologies Market, 2015-2025

出版商 ROOTS ANALYSIS 商品編碼 335339
出版日期 內容資訊 英文 202 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品防止仿冒技術的全球市場 Pharmaceutical Anti-Counterfeiting Technologies Market, 2015-2025
出版日期: 2015年07月06日 內容資訊: 英文 202 Pages
簡介

產品仿冒是全球所有產業共通的課題,不過,在醫藥品產業中不單是招致產業界的商業性損失,也嚴重涉及患者的健康和性命。

本報告以醫藥品防止仿冒技術的全球市場為焦點,提供各種技術的主要特長、依據目前趨勢的市場預測、SWOT分析、市場發展的影響因素等多方面的分析資訊彙整、預防仿冒的先進技術、降低成本及普及方策等解說、市場整體情況、短中期(2015-2020年)及長期(2020-2025年)預測數值。

第1章 序

  • 報告的對象範圍
  • 調查方法
  • 各章的概要

第2章 摘要整理

第3章 簡介

  • 仿冒醫藥品:醫藥品產業聳立的應克服的巨大課題
  • 假藥的各種定義
  • 在醫藥品產業內中助長仿冒的因素
  • 防止仿冒策略、技術的必要性
  • 仿冒的危險性的認識與評估
  • 醫藥品產業上近來的仿冒事件
  • 線上藥品銷售的仿冒程度
  • 製藥公司及監督機構對仿冒問題的措施
  • 各種防止仿冒技術

第4章 市場概要

  • 本章的概要
  • 防止仿冒技術
  • 跨不同技術的完善平台
  • 構成表面功能的技術
    • 全像技術
    • 變色性墨水及標註
    • 產品上的標註
    • 安全圖形
    • 其他技術
  • 構成隱藏功能的技術
    • 內建式圖形、標籤
    • 透明墨水、印刷
    • 數位浮水印及隱藏標註
    • DNA標記、標籤劑
    • 其他技術
  • 追蹤技術
    • 序列化
    • 條碼
    • 無線標籤(RFID)
    • 特殊表面標註
    • 電子履歷(ePedigree)、行動履歷(mPedigree)
    • 其他追蹤技術
  • 防止仿冒技術比較
    • 製造商觀點
    • 使用者的觀點

第5章 認證法 - 主要企業技術

  • 本章的概要
  • AlpVision
  • Applied DNA Sciences
  • InfraTrac
  • Amcor
  • LinkSmart
  • VorVision
  • Schreiner ProSecure
  • ACG-Worldwide
  • 其他

第6章 追蹤法 - 主要技術和序列化的概念

  • 本章的概要
  • 序列化 - 其意義
  • 製藥公司的序列化的優點
  • 對序列化有利的法律
  • 序列化引進的課題
  • 追蹤技術
    • Axway的技術
    • Sproxil的技術
    • mPedigree Network的技術
    • SecureRF的技術
    • TruTag的技術
    • 其他追蹤技術
  • 無線標籤(RFID)利用的技術
    • Alien Technology的RFID平台
    • 3M的RFID
    • SMARTRAC的RFID平台
    • EM Microelectronics的智慧型RFID
    • Avery Dennison的RFID平台
  • 序列化的案例研究
  • 序列化 - 現狀的地位

第7章 市場預測

  • 本章的概要
  • 預測方法
  • 重要前提條件
  • 醫藥品防止仿冒技術市場 - 全體:2015-2025年
  • 提供表面功能的醫藥品防止仿冒技術:2015-2025年
  • 提供隱藏功能的醫藥品防止仿冒技術:2015-2025年
  • 各地區市場預測
  • 比較摘要

第8章 SWOT分析

第9章 採訪筆記本

第10章 結論

  • 依據巨大的市場能力預測穩定成長的防止仿冒技術
  • 序列化是短期對策的主流
  • 認證技術表面功能解決方案構成比擴大
  • 對防止仿冒技術有貢獻的最大區域是美國和歐洲
  • 結論

第11章 附錄 1:表格形式資料

第12章 附錄 2:企業、團體一覽

圖表一覽

目錄
Product Code: RA10042

The problem of counterfeit products has been a common challenge to all the industries across the globe. However, when it comes to the pharmaceutical industry, the issue primarily revolves around the health of patients rather than revenue losses in the industry. Counterfeit drugs create substantial public health hazards and cause crucial safety concerns. Falsified or substandard drugs can lead to adverse reactions / side effects and consequently lead to the death of a patient.

The major challenge associated with a counterfeit drug is that a non-expert, such as a patient, cannot differentiate between genuine and counterfeit drug without the help of a special instrument or device. The packaging, shape and size of counterfeit drugs are made identical to that of an authentic drug by the counterfeiters. However, counterfeit drugs contain very less or no active ingredient; instead, they contain other useless and harmful materials such as dust, chalk or very low quality active ingredients posing serious threats to the patients. These issues have led to the development of many technologies that can be used to detect whether a drug is legitimate or fake. Apart from these technologies, many other significant measures have been taken by the pharmaceutical companies and government authorities to tackle this growing problem.

The market can be categorised into two segments, Authentication Technologies (the technologies providing overt and covert security features) and Track & Trace Technologies (the technologies facilitating visibility of products throughout the supply chain). Specifically in the Authentication segment, technologies providing covert security features are very popular and occupy a major share in of the overall authentication market. These technologies are very difficult to mimic and require special instruments / devices for verification of drugs by the manufacturers.

Managing supply chain, especially in case of pharmaceutical industry, is a big challenge. Pharmaceuticals supply chains are highly complex and therefore make it an ideal target for counterfeiters. However, recently many developments have taken place to overcome this challenge. Several countries across the globe have passed legislations, making it mandatory to implement serialisation by the manufacturers. Serialisation is being thought as a one stop solution to prevent counterfeiting in the pharmaceutical industry by securing the supply chain.

The field has attracted several companies which have developed many technologies with an aim to prevent counterfeiting in the pharma industry. The overall interest continues to rise as is evident from the number of counterfeit incidents and various laws and legislations being passed throughout the world. Small companies that have developed anti-counterfeiting technologies are likely to play a very active role in the near future.

Synopsis

The ‘Pharmaceutical Anti-Counterfeiting Technologies, 2015-2025’ report provides a comprehensive study of the growing market of anti-counterfeiting technologies being used in the pharmaceutical industry. This study provides extensive details on technologies which offer overt and covert features to enable verification of drugs. In addition, it reviews the different track and trace technologies which enable tracking of a product through the supply chain. Counterfeiting of products is a big concern in several industries such as electronics, cosmetics, tobacco, wine & spirits and fast moving consumer goods. Specifically, within the pharmaceutical market, the magnitude of the problem is relatively high as it has a direct impact on the health of the wider community. It is worth highlighting that the pharmaceutical market is highly attractive for counterfeiters due to several benefits such as high price of patented drugs, lack of proper legislations and high demand of medicinescompared to their supply. The primary goal of anti-counterfeiting technologies is to prevent counterfeiting of products; this is done by making it difficult to copy patent protected drugs as well as preventing entry of substandard or fake drugs into the product supply chain.

The report covers multiple aspects such as key features of various technologies, scenario based future outlook of the market, SWOT analysis and our opinion on the likely drivers which will influence the market’s evolution. We have provided a holistic view of the market landscape including detailed profiles of leading technologies highlighting the process by which they prevent counterfeiting. Further advancements in such technologies will make them more cost effective, encourage a wider adoption and result in a more mature market in the years to come.

In addition to the key benefits and the likely market drivers, this study also highlights some of the challenges associated with the use and implementation of these technologies in the pharmaceutical industry. Certain technologies require modifications in existing production processes and present operational challenges to the manufacturers. Cost is another factor that can significantly restrain the market.

The report also includes two case studies on serialisation. We have looked at the regulations that have been implemented already or are likely to be implemented to prevent counterfeiting. Most of these regulations favour item level serialisation as a task to be accomplished by the pharmaceutical manufacturers in the near future. However, some stakeholders are of the opinion that authentication technologies are much more effective as anti-counterfeiting measures rather than just providing a unique number to each product (the case of serialisation). The report covers various techniques and measures that have the potential to combat the challenges related to counterfeit medicines.

The scenario based forecast approach identifies short-midterm and long term market evolution for the period 2015-2020 and 2020-2025, respectively. The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research.

Example Highlights

  • 1. During our research, we identified over 100 technologies (including both authentication and track & trace technologies) developed by over 70 different companies. The landscape seems to be fairly well distributed between authentication and track & trace technologies. Due to the versatility of these technologies, they have wider applications in other industries making it highly lucrative for the current stakeholders.
  • 2. Some solutions offer multiple features covering all forms of anti-counterfeiting approach; examples include N’Crypt (Amcor), CATS (Authentix), digital DNA (Applied DNA Sciences), nonclonable ID (Bilcaretech), TruTag Platform (TruTag Technologies) and Microparticle Technology (Stealth Mark).
  • 3. As an industry, the focus seems to be divided between authentication and serialisation technologies; stakeholders view this both as a challenge as well as an opportunity to foster further innovation.There is a wider consensus that puts the onus back on different stakeholders to work collaboratively so that the opportunities can be monetised at a rapid pace; this will result in more robust and complex solutions likely to provide the required security to consumers and companies alike.
  • 4. Many regions, including the EU and the US, have passed legislations that make serialisation mandatory for every pharmaceutical product. It is a very promising move that is likely to result in a paradigm shift in the way supply chains are managed today. However, there are several implementation hurdles which are expected to result in delays, providing a window of opportunity to the counterfeiters to take advantage of.
  • 5. It is a known fact that most of counterfeiting happens in India and China. Though the focus on emerging markets has been relatively week so far, manufacturing companies are expected to increase their attention to deploy anti-counterfeiting technologies for products being manufactured or intended to be launched in these regions; going forward, we expect these markets to play a more prominent role in the overall growth of the opportunity.

Research Methodology

Most of the data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Research Methodology

Most of the data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of major highlights captured in the report. It offers a high level view on the likely future of anti-counterfeiting technologies in the pharmaceutical industry.

Chapter 3 provides a general introduction to the anti-counterfeiting technologies. It identifies the needs and challenges faced by the pharmaceutical industry due to counterfeiting and highlights the extent of this problem. We have included examples of the products from leading pharmaceutical companies that have been counterfeited.

Chapter 4 provides a comprehensive analysis of the current market of anti-counterfeiting technologies. It lists more than 100 technologies that can be used to prevent counterfeiting; these technologies have been categorised as authentication technologies (offering overt and / or covert features) and track and trace technologies (including serialisation, RFID, barcodes, e-pedigree / m-pedigree).

Chapter 5 provides details of the well-known and emerging anti-counterfeiting technologies worldwide. This chapter covers insights on the companies developing these technologies as well as details of how the technologies help prevent counterfeiting by highlighting their unique features and applicability.

Chapter 6 presents a detailed discussion covering the developments related to serialisation. As a lot of countries have passed regulations making serialisation mandatory in the near future, there is a dramatic shift currently taking place in terms of how the pharmaceutical supply chains are likely to be managed in the future.

Chapter 7 highlights the likely future evolution of anti-counterfeiting technologies in pharmaceutical industry over the next ten years. We have adopted a scenario based approach to discuss the evolution of authentication technologies offering overt and covert features, across different regions, till 2025.

Chapter 8 provides the SWOT analysis of anti-counterfeiting technologies market giving strategic insights to the major factors that have contributed to the growth of this market. It also highlights the weaknesses and threats that can negatively impact the growth of the market.

Chapter 9 is a collection of interview transcripts; for the purposes of this study, we held discussions with experts from AlpVision, InfraTrac, Sproxil and Jura JSP to ascertain the key strategic initiatives and future roadmap of the industry.

Chapter 10 summarises the overall report. In this chapter, we have provided a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 11 is an appendix, which provides tabulated data and numbers for all the figures presented in the report.

Chapter 12 is an appendix, which provides a list of companies and organisations mentioned in this report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Counterfeit Drugs: A Mammoth Challenge to Overcome in Pharmaceutical Industry
  • 3.2. Different Definitions of a Counterfeit Drug
  • 3.3. Factors Encouraging Counterfeiting in Pharmaceutical Industry
  • 3.4. Need for Anti-Counterfeiting Measures/Technologies
    • 3.4.1. Counterfeit Drug Cases: Yearly Distribution
  • 3.5. Identification and Assessment of Risks From Counterfeiting
    • 3.5.1. Determining The Severity of a Counterfeit Incident
    • 3.5.2. Determining The Possibility of Occurrence of a Counterfeit Incident
  • 3.6. Recent Counterfeiting Incidents in Pharmaceutical Industry
    • 3.6.1. Counterfeit Cialis (Tadalafil) Tablets
    • 3.6.2. Counterfeit Viagra (Sildenafil Citrate) Tablets
    • 3.6.3. Counterfeit Serostim (Somatropin) Drug
    • 3.6.4. Counterfeit Procrit (Epoetin Alfa) Injection
    • 3.6.5. Other Counterfeited Drugs
  • 3.7. Extent of Counterfeiting Through Online Pharmacies
    • 3.7.1. Russia Becoming a Major Source of Online Counterfeit Drugs Market
    • 3.7.2. Presence of Counterfeit Botox in an Online Pharmacy
    • 3.7.3. Hundreds of Counterfeiters Arrested in China for Selling Counterfeit Drugs Over the Internet
    • 3.7.4. Novo Nordisk's Stolen Human Growth Hormone Sold Online
    • 3.7.5. Coordinated Sweep to Attack Online Pharmacies Selling Unauthorised Drugs
    • 3.7.6. A Hint to Source of Drugs for Illegal Online Pharmacies
    • 3.7.7. Launch of BeSafeRx by FDA to Create Awareness About Online Pharmacies
  • 3.8. Initiatives Taken by Pharmaceutical Companies / Government Authorities To Combat Counterfeiting Problem
    • 3.8.1. International Medical Product Anti-Counterfeiting Task Force (IMPACT)
    • 3.8.2. Operation Pangea
    • 3.8.3. Establishment of Interface Public-Members (IPM) by World Customs Organisation
    • 3.8.4. Launch of PASS System by Pfizer
    • 3.8.5. Sanofi's Commitment: Creation of Central Anti-Counterfeiting Laboratory
    • 3.8.6. Role of Eli Lilly And Company in Fighting Counterfeiters
    • 3.8.7. Merck's Responsibility Towards Prevention of Counterfeiting in Pharma Industry
  • 3.9. Different Anti-Counterfeiting Technologies
    • 3.9.1. Authentication Technologies Providing Overt Features
    • 3.9.2. Authentication Technologies Providing Covert Features
    • 3.9.3. Track and Trace Technologies

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Anti-Counterfeiting Technologies
  • 4.3. Platforms are Well-Distributed Across Different Technologies
  • 4.4. Technologies Providing Overt Features
    • 4.4.1. Holograms
    • 4.4.2. Colour Shift Inks / Markings
    • 4.4.3. On-Product Markings
    • 4.4.4. Security Graphics
    • 4.4.5. Other Technologies
  • 4.5. Technologies Providing Covert Features
    • 4.5.1. Embedded Graphics / Labels
    • 4.5.2. Invisible Inks / Printings
    • 4.5.3. Digital Watermarks and Hidden Marks
    • 4.5.4. DNA Markers / Taggants
    • 4.5.5. Other Technologies
  • 4.6. Track and Trace Technologies
    • 4.6.1. Serialisation
    • 4.6.2. Barcode
    • 4.6.3. RFID
    • 4.6.4. Unique Surface Marking
    • 4.6.5. e-pedigree/m-pedigree
    • 4.6.6. Other Track and Trace Technologies
  • 4.7. Comparison Amongst Anti-Counterfeiting Technologies
    • 4.7.1. Manufacturer's Perspective
      • 4.7.1.1. Level of Security
      • 4.7.1.2. Implementation Ease
      • 4.7.1.3. Robustness/Durability
    • 4.7.2. User's Perspective
      • 4.7.2.1. Cost
      • 4.7.2.2. User Friendliness
      • 4.7.2.3. Level of Complexity

5. AUTHENTICATION: KEY PLAYERS AND TECHNOLOGIES

  • 5.1. Chapter Overview
  • 5.2. Technologies by AlpVision
    • 5.2.1. About AlpVision
    • 5.2.2. Anti Counterfeiting Solutions
      • 5.2.2.1. Cryptoglyph
    • 5.2.3. Fingerprint
    • 5.2.4. Benefits for Manufacturers and Consumers
    • 5.2.5. Krypsos
  • 5.3. Technologies by Applied DNA Sciences
    • 5.3.1. About Applied DNA Sciences
    • 5.3.2. SigNature® DNA Technology
      • 5.3.2.1. SigNature® DNA Marker Production
      • 5.3.2.2. Applications of SigNature® DNA Technology
    • 5.3.3. digitalDNA® Technology
      • 5.3.3.1. digitalDNA® Deployment
      • 5.3.3.2. Applications of digitalDNA® Technology
    • 5.3.4. Recent Developments
      • 5.3.4.1. Launch of DNA Taggant and On-Site Authentication for Pharmaceutics
      • 5.3.4.2. Launch of DNA BeaconTM
      • 5.3.4.3. Collaboration with ITW Pillar Technologies
  • 5.4. Technology by InfraTrac
    • 5.4.1. About InfraTrac
    • 5.4.2. Anti Counterfeiting Solutions
      • 5.4.2.1. Usage
      • 5.4.2.2. Advantages / Features of InfraTrac
      • 5.4.2.3. Benefits for Manufacturers
  • 5.5. Technologies by Amcor
    • 5.5.1. About Amcor
    • 5.5.2. N'Crypt® Security Solution
    • 5.5.3. Benefits of N'Crypt® Security Solution
  • 5.6. Technologies by LinkSmart
    • 5.6.1. About LinkSmart technologies
    • 5.6.2. About smartDNATM Technology
      • 5.6.2.1. Working of smartDNATM Technology
      • 5.6.2.2. Benefits for Manufacturers
  • 5.7. Technologies by VorVision®
    • 5.7.1. About VorVision®
    • 5.7.2. VorCode Technology
    • 5.7.3. Working of the Technology
  • 5.8. Technologies by Schreiner ProSecure
    • 5.8.1. Holograms
    • 5.8.2. Colour Shifting Inks
    • 5.8.3. LaserSecure
    • 5.8.4. FluxSecure
    • 5.8.5. DNASecure
    • 5.8.6. BitSecure
    • 5.8.7. Track and Trace Technologies
  • 5.9. Technologies by ACG-Worldwide
    • 5.9.1. Brandshield Printing
    • 5.9.2. Brandshield 3600 Printing
    • 5.9.3. Engraving on Capsule
    • 5.9.4. Tablets of Complex Shape
    • 5.9.5. Brandshield Galaxy
    • 5.9.6. Verif-i
  • 5.10. Other Technologies
    • 5.10.1. DigiTrack by Catalent Pharma
    • 5.10.2. DNA Matrix by DNA Technologies
    • 5.10.3. Technologies by Everest Holovisions
      • 5.10.3.1. Holographic Shrink Sleeves
      • 5.10.3.2. Holographic Film
    • 5.10.4. Technologies by Dupont
      • 5.10.4.1. Izon Technology
      • 5.10.4.2. Dupont Traceology
    • 5.10.5. Microparticle Technology by StealthMark
    • 5.10.6. Technologies by Raumedic
      • 5.10.6.1. Micro-Particle Technology
      • 5.10.6.2. UV-Marking
    • 5.10.7. μicroTag Technology by MicroTag Temed
    • 5.10.8. SAVEmed by Nano 4 U
    • 5.10.9. TagSure Technology by InkSure
    • 5.10.10. TruScan by ThermoScientific

6. TRACK AND TRACE: KEY TECHNOLOGIES AND THE CONCEPT OF SERIALISATION

  • 6.1. Chapter Overview
  • 6.2. Serialisation: What Does it Mean?
  • 6.3. Benefits of Serialisation For Pharmaceutical Manufacturers
  • 6.4. Legislations / Laws / Acts in Favour of Serialisation
    • 6.4.1. The Drug Quality and Security Act (DQSA-H.R. 3204)
    • 6.4.2. The EU Directive on Falsified Medicines
    • 6.4.3. Legislations / Regulations in Asian Countries
    • 6.4.4. Legislations / Regulations In Other Countries
  • 6.5. Challenges to Implementation of Serialisation
  • 6.6. Track and Trace Technologies
    • 6.6.1. Technology by Axway
      • 6.6.1.1. About Axway
      • 6.6.1.2. Axway Track and Trace Technology
    • 6.6.2. Technologies by Sproxil
      • 6.6.2.1. Mobile Product Authentication (MPA)
      • 6.6.2.2. Cascading Authentication
    • 6.6.3. Technology by mPedigree Network
      • 6.6.3.1. About mPedigree Network
      • 6.6.3.2. GoldkeysTM Platform
    • 6.6.4. Technologies by SecureRF
      • 6.6.4.1. Veridify
      • 6.6.4.2. LIME Tag Solution
    • 6.6.5. Technology by TruTag® Technologies
      • 6.6.5.1. About TruTag® Technologies
      • 6.6.5.2. TruTag® MicroTag Platform
    • 6.6.6. Other Track and Trace Technologies
      • 6.6.6.1. AuthentiTrack by Covectra
      • 6.6.6.2. Comprehensive Authentication and Traceability System (CATS) by Authentix
      • 6.6.6.3. CPS (Carton Printing and Verification System) by Bosch Packaging Systems
      • 6.6.6.4. DVAC (Drug Verification and Compliance) Framework by Portalis
      • 6.6.6.5. Life Sciences Cloud by TraceLink
      • 6.6.6.6. Medtracker by Atlantic Zeiser
      • 6.6.6.7. Naginels Technology
      • 6.6.6.8. nonClonableID Technology by Bilcare Technologies
      • 6.6.6.9. Technologies by PharmaSecure
      • 6.6.6.10. StratOmark by Sekuworks
  • 6.7. RFID Based Technologies
    • 6.7.1. RFID Platform by Alien Technology
    • 6.7.2. RFID by 3M
    • 6.7.3. RFID Platform by SMARTRAC
    • 6.7.4. Intelligent RFID by EM Microelectronics
    • 6.7.5. RFID Platform by Avery Dennison
  • 6.8. Case Studies On Serialisation
    • 6.8.1. Case Study 1: Cognizant-An IT Services Company Providing Serialisation Solution
    • 6.8.2. Case Study 2: Recipharm-A Contract Development and Manufacturing Organisation
  • 6.9. Serialisation: Mapping the Current Scenario

7. MARKET FORECAST

  • 7.1. Chapter Overview
  • 7.2. Forecast Methodology
  • 7.3. Key Assumptions
  • 7.4. Overall Pharma Anti-Counterfeiting Technologies Market, 2015-2025
  • 7.5. Anti-Counterfeiting Technologies Providing Covert Features, 2015-2025
  • 7.6. Anti-Counterfeiting Technologies Providing Overt Features, 2015-2025
  • 7.7. Regional Market Forecast
  • 7.8. Comparative Summary

8. SWOT ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Strengths
    • 8.2.1. Technologies Offer Multiple Security Features
    • 8.2.2. User Friendliness
    • 8.2.3. Unchanged Production Lines
  • 8.3. Weaknesses
    • 8.3.1. Some Technologies Are Easy to Replicate
    • 8.3.2. Technologies are Costly to Deploy
    • 8.3.3. Lack of End User Awareness
  • 8.4. Opportunities
    • 8.4.1. Serialisationas a Mandatory Process
    • 8.4.2. Growing Presence in Emerging Markets
    • 8.4.3. Versatility of Technologies
  • 8.5. Threats
    • 8.5.1. Divided Focus Between Authentication and Serialisation
    • 8.5.2. Challenging Timelines

9. INTERVIEW TRANSCRIPTS

  • 9.1. Interview 1: Dr. Fred Jordan, CEO, AlpVision
  • 9.2. Interview 2: Jaime Stern, Director of Sales, Sproxil
  • 9.3. Interview 3: Dr. Sharon Flank, CEO, InfraTrac
  • 9.4. Interview 4: Roger Pallacivini, Sales Director Europe, Jura JSP GmbH

10. CONCLUSION

  • 10.1. With a Huge Market Potential, Anti-Counterfeiting Technologies Market to Grow Steadily
  • 10.2. Serialisation to Dominate the Discussions in the Short Term
  • 10.3. Solutions Offering Covert Features will Gain Additional Market Share Within Authentication Technologies
  • 10.4. The US and The EU will Remain Leading Contributors to Anti-Counterfeiting Technologies
  • 10.5. Concluding Remarks

11. APPENDIX 1: TABULATED DATA

12. APPENDIX 2: COMPANIES AND ORGANISATIONS LISTED

List of Figures:

  • Figure 3.1: Counterfeit Drug Cases Opened: Distribution by Year
  • Figure 3.2: Number of Counterfeit Drugs Cases Detected: Distribution by Year
  • Figure 3.3: Geographical Distributions of the Counterfeit Drug Cases in 2014
  • Figure 4.1: Anti-Counterfeiting Technologies: Distribution by Type of Features
  • Figure 4.2: Comparisons Amongst Anti-Counterfeiting Technologies
  • Figure 6.1: Serialisation: Mapping the Current Scenario
  • Figure 7.1: Future Market Scenarios: Description
  • Figure 7.2: Overall Pharma Anti-Counterfeiting Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Million)
  • Figure 7.3: Overall Pharma Anti-Counterfeiting Technologies Market, Long term (2020-2025): Base Scenario (USD Million)
  • Figure 7.4: Anti-Counterfeiting Technologies Providing Covert Features, Short-Midterm (2015-2020): Base Scenario (USD Million)
  • Figure 7.5: Anti-Counterfeiting Technologies Providing Covert Features, Long Term (2020-2025): Base Scenario (USD Million)
  • Figure 7.6: Anti-Counterfeiting Technologies Providing Overt Features, Short-Midterm (2015-2020): Base Scenario (USD Million)
  • Figure 7.7: Anti-Counterfeiting Technologies Providing Overt Features, Long Term (2020-2025): Base Scenario (USD Million
  • Figure 7.8: Regional Market Forecast, Short-Midterm (2015-2020): Base Scenario (USD Million)
  • Figure 7.9: Regional Market Forecast, Long Term (2020-2025): Base Scenario (USD Million)
  • Figure 7.10: Market Scenarios, Comparative Positioning (USD Million)
  • Figure 7.11: Market Scenarios: Comparative Annual Growth Rates
  • Figure 10.1: Anti-Counterfeiting Technologies: Comparative Market Evolution Scenarios, 2015, 2020, 2025 (USD Million)
  • Figure 10.2: Anti-Counterfeiting Technologies: Regional Comparative Market Evolution, Base Case Scenario, 2015, 2020, 2025 (USD Million)

List of Tables:

  • Table 4.1: List of Anti-Counterfeiting Technologies
  • Table 4.2: Anti-Counterfeiting Technologies: Distribution by Features
  • Table 4.3: Technologies Providing Overt Features: Advantages and Disadvantages
  • Table 4.4: List of Hologram Technologies
  • Table 4.5: List of Colour Shift Ink / Marking Technologies
  • Table 4.6: List of On-Product Marking Technologies
  • Table 4.7: List of Security Graphic Technologies
  • Table 4.8: List of Other Technologies Providing Overt Features
  • Table 4.9: Technologies Providing Covert Features: Advantages and Disadvantages
  • Table 4.10: List of Embedded Graphic / Label Technologies
  • Table 4.11: List of Invisible Ink / Printing Technologies
  • Table 4.12: List of Digital Watermark and Hidden Marking Technologies
  • Table 4.13: List of DNA Marker / Taggant Technologies
  • Table 4.14: List of Other Technologies Providing Covert Features
  • Table 4.15: Track and Trace Technologies: Advantages and Disadvantages
  • Table 4.16: List of Serialisation Technologies
  • Table 4.17: List of Barcode Technologies
  • Table 4.18: List of RFID Technologies
  • Table 4.19: List of Unique Surface Marking Technologies
  • Table 4.20: List of e-pedigree/m-pedigree Technologies
  • Table 4.21: List of Other Track and Trace Technologies
  • Table 8.1: SWOT Analysis
  • Table 11.1: Counterfeiting Drug Cases Opened: Distribution by Year
  • Table 11.2: Number of Counterfeit Drugs Cases Detected: Distribution by Year
  • Table 11.3: Geographical Distribution of Counterfeit Drug Cases in 2014
  • Table 11.4: Overall Pharma Anti-Counterfeiting Technologies Market, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
  • Table 11.5: Overall Pharma Anti-Counterfeiting Technologies Market, Short -Midterm (2015-2020): Base Scenario (USD Million)
  • Table 11.6: Overall Pharma Anti-Counterfeiting Technologies Market, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
  • Table 11.7: Overall Pharma Anti-Counterfeiting Technologies Market, Long term (2020-2025): Conservative Scenario (USD Million)
  • Table 11.8: Overall Pharma Anti-Counterfeiting Technologies Market, Long term (2020-2025): Base Scenario (USD Million)
  • Table 11.9: Overall Pharma Anti-Counterfeiting Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Million)
  • Table 11.10: Anti-Counterfeiting Technologies Providing Overt Features, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
  • Table 11.11: Anti-Counterfeiting Technologies Providing Overt Features, Short -Midterm (2015-2020): Base Scenario (USD Million)
  • Table 11.12: Anti-Counterfeiting Technologies Providing Overt Features, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
  • Table 11.13: Anti-Counterfeiting Technologies Providing Overt Features, Long term (2020-2025): Conservative Scenario (USD Million)
  • Table 11.14: Anti-Counterfeiting Technologies Providing Overt Features, Long term (2020-2025): Base Scenario (USD Million)
  • Table 11.15: Anti-Counterfeiting Technologies Providing Overt Features, Long term (2020-2025): Optimistic Scenario (USD Million)
  • Table 11.16: Anti-Counterfeiting Technologies Providing Covert Features, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
  • Table 11.17: Anti-Counterfeiting Technologies Providing Covert Features, Short -Midterm (2015-2020): Base Scenario (USD Million)
  • Table 11.18: Anti-Counterfeiting Technologies Providing Covert Features, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
  • Table 11.19: Anti-Counterfeiting Technologies Providing Covert Features, Long term (2020-2025): Conservative Scenario (USD Million)
  • Table 11.20: Anti-Counterfeiting Technologies Providing Covert Features, Long term (2020-2025): Base Scenario (USD Million)
  • Table 11.21: Anti-Counterfeiting Technologies Providing Covert Features, Long term (2020-2025): Optimistic Scenario (USD Million)
  • Table 11.22: Holograms Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
  • Table 11.23: Holograms Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
  • Table 11.24: Holograms Market Forecast, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
  • Table 11.25: Holograms Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
  • Table 11.26: Holograms Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
  • Table 11.27: Holograms Market Forecast, Long term (2020-2025): Optimistic Scenario (USD Million)
  • Table 11.28: Colour Shift Inks Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
  • Table 11.29: Colour Shift Inks Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
  • Table 11.30: Colour Shift Inks Market Forecast, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
  • Table 11.31: Colour Shift Inks Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
  • Table 11.32: Colour Shift Inks Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
  • Table 11.33: Colour Shift Inks Market Forecast, Long term (2020-2025): Optimistic Scenario (USD Million)
  • Table 11.34: Security Graphics Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
  • Table 11.35: Security Graphics Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
  • Table 11.36: Security Graphics Market Forecast, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
  • Table 11.37: Security Graphics Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
  • Table 11.38: Security Graphics Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
  • Table 11.39: Security Graphics Market Forecast, Long term (2020-2025): Optimistic Scenario (USD Million)
  • Table 11.40: Other Technologies Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
  • Table 11.41: Other Technologies Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
  • Table 11.42: Other Technologies Market Forecast, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
  • Table 11.43: Other Technologies Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
  • Table 11.44: Other Technologies Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
  • Table 11.45: Other Technologies Market Forecast, Long term (2020-2025): Optimistic Scenario (USD Million)
  • Table 11.46: Invisible Printing Technologies Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
  • Table 11.47: Invisible Printing Technologies Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
  • Table 11.48: Invisible Printing Technologies Market Forecast, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
  • Table 11.49: Invisible Printing Technologies Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
  • Table 11.50: Invisible Printing Technologies Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
  • Table 11.51: Invisible Printing Technologies Market Forecast, Long term (2020-2025): Optimistic Scenario (USD Million)
  • Table 11.52: Digital Watermarks Technologies Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
  • Table 11.53: Digital Watermarks Technologies Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
  • Table 11.54: Digital Watermarks Technologies Market Forecast, Short -Midterm (2015 -2020): Optimistic Scenario (USD Million)
  • Table 11.55: Digital Watermarks Technologies Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
  • Table 11.56: Digital Watermarks Technologies Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
  • Table 11.57: Digital Watermarks Technologies Market Forecast, Long term (2020-2025): Optimistic Scenario (USD Million)
  • Table 11.58: DNA Markers / Taggant Technologies Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
  • Table 11.59: DNA Markers / Taggant Technologies Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
  • Table 11.60: DNA Markers / Taggant Technologies Market Forecast, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
  • Table 11.61: DNA Markers / Taggant Technologies Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
  • Table 11.62: DNA Markers / Taggants Technologies Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
  • Table 11.63: DNA Markers / Taggants Technologies Market Forecast, Long term (2020 -2025): Optimistic Scenario (USD Million)
  • Table 11.64: Hidden Marks and Printing Technologies Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
  • Table 11.65: Hidden Marks and Printing Technologies Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
  • Table 11.66: Hidden Marks and Printing Technologies Market Forecast, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
  • Table 11.67: Hidden Marks and Printing Technologies Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
  • Table 11.68: Hidden Marks and Printing Technologies Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
  • Table 11.69: Hidden Marks and Printing Technologies Market Forecast, Long term (2020-2025): Optimistic Scenario (USD Million)
  • Table 11.70: Other Technologies Market Forecast, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
  • Table 11.71: Other Technologies Market Forecast, Short -Midterm (2015-2020): Base Scenario (USD Million)
  • Table 11.72: Other Technologies Market Forecast, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
  • Table 11.73: Other Technologies Market Forecast, Long term (2020-2025): Conservative Scenario (USD Million)
  • Table 11.74: Other Technologies Market Forecast, Long term (2020-2025): Base Scenario (USD Million)
  • Table 11.75: Other Technologies Market Forecast, Long term (2020-2025): Optimistic Scenario (USD Million)
  • Table 11.76: Regional Market Forecast: North America, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
  • Table 11.77: Regional Market Forecast: North America, Short -Midterm (2015-2020): Base Scenario (USD Million)
  • Table 11.78: Regional Market Forecast: North America, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
  • Table 11.79: Regional Market Forecast: North America, Long term (2020-2025): Conservative Scenario (USD Million)
  • Table 11.80: Regional Market Forecast: North America, Long term (2020-2025): Base Scenario (USD Million)
  • Table 11.81: Regional Market Forecast: North America, Long term (2020-2025): Optimistic Scenario (USD Million)
  • Table 11.82: Regional Market Forecast: EU 5, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
  • Table 11.83: Regional Market Forecast: EU 5, Short -Midterm (2015-2020): Base Scenario (USD Million)
  • Table 11.84: Regional Market Forecast: EU 5, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
  • Table 11.85: Regional Market Forecast: EU 5, Long term (2020-2025): Conservative Scenario (USD Million)
  • Table 11.86: Regional Market Forecast: EU 5, Long term (2020-2025): Base Scenario (USD Million)
  • Table 11.87: Regional Market Forecast: EU 5, Long term (2020-2025): Optimistic Scenario (USD Million)
  • Table 11.88: Regional Market Forecast: Developed Asia, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
  • Table 11.89: Regional Market Forecast: Developed Asia, Short -Midterm (2015-2020): Base Scenario (USD Million)
  • Table 11.90: Regional Market Forecast: Developed Asia, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
  • Table 11.91: Regional Market Forecast: Developed Asia, Long term (2020-2025): Conservative Scenario (USD Million)
  • Table 11.92: Regional Market Forecast: Developed Asia, Long term (2020-2025): Base Scenario (USD Million)
  • Table 11.93: Regional Market Forecast: Developed Asia, Long term (2020-2025): Optimistic Scenario (USD Million)
  • Table 11.94: Regional Market Forecast: Rest of the World, Short -Midterm (2015-2020): Conservative Scenario (USD Million)
  • Table 11.95: Regional Market Forecast: Rest of the World, Short -Midterm (2015-2020): Base Scenario (USD Million)
  • Table 11.96: Regional Market Forecast: Rest of the World, Short -Midterm (2015-2020): Optimistic Scenario (USD Million)
  • Table 11.97: Regional Market Forecast: Rest of the World, Long term (2020-2025): Conservative Scenario (USD Million)
  • Table 11.98: Regional Market Forecast: Rest of the World, Long term (2020-2025): Base Scenario (USD Million)
  • Table 11.99: Regional Market Forecast: Rest of the World, Long term (2020-2025): Optimistic Scenario (USD Million)
  • Table 11.100: Market Scenarios, Comparative Positioning (USD Million)
  • Table 11.101: Market Scenarios, Comparative Annual Growth Rates (USD Million)
  • Table 11.102: Anti-Counterfeiting Technologies Market: Comparative Market Evolution Scenarios, 2015, 2020, 2025 (USD Million)

List of Companies

Following Companies / Organisations / Government Agencies have been mentioned in this report:

  • 1. 3M
  • 2. 3S Simons Security Systems
  • 3. ACG-Worldwide
  • 4. Acsis
  • 5. Alcan Packaging
  • 6. Alien Technology
  • 7. Alliance for Safe Online Pharmacies
  • 8. AlpVision
  • 9. Amcor
  • 10. Amgen
  • 11. Applied DNA Sciences
  • 12. Atlantic Zeiser
  • 13. Authentix
  • 14. Avery Dennison
  • 15. Axway
  • 16. Ball Packaging
  • 17. Bilcaretech
  • 18. Biocode
  • 19. Bosch Packaging Technology
  • 20. Canadadrugs.com
  • 21. Catalent Pharma
  • 22. Cellular Bioengineering
  • 23. Central Anti-Counterfeiting Laboratory
  • 24. Chesapeake (Acquired by The Carlyle Group)
  • 25. Cognizant
  • 26. Confidex
  • 27. Coresonant
  • 28. Covectra
  • 29. Deutsche Welle
  • 30. DiNova Venture Capital
  • 31. DNA Technologies
  • 32. Dupont
  • 33. Eli Lilly and Company
  • 34. EM Microelectronics
  • 35. European Alliance of Access to Safe Medicines
  • 36. European Medicines Agency
  • 37. Everest Holovisions
  • 38. Flint Group
  • 39. Genzyme
  • 40. Green Project Inc
  • 41. IC-Tag Solutions
  • 42. Impinj
  • 43. InfraTrac
  • 44. Ingenia Technology
  • 45. InkSure Technologies
  • 46. Intermec
  • 47. International Medical Product Anti-Counterfeiting Task Force (IMPACT)
  • 48. Interpol
  • 49. Invengo
  • 50. Isotag
  • 51. ITW Pillar Technologies
  • 52. Jura JSP
  • 53. Klocke Group
  • 54. Kutterer&Mauer AG
  • 55. Lab-ID
  • 56. Laxcen
  • 57. LinkSmart Technologies
  • 58. Maryland School of Pharmacy
  • 59. Merck
  • 60. Merck Serono
  • 61. MetalCraft
  • 62. Micros Chip
  • 63. MicroTagTemed Ltd.
  • 64. Microtrace Solutions
  • 65. Mobia Solutions
  • 66. mPedigree
  • 67. Nano 4 U
  • 68. National Association of Boards of Pharmacy
  • 69. Neosid
  • 70. North America Security Products Organisation Company
  • 71. NovaVision
  • 72. Novo Nordisk
  • 73. Oat Systems
  • 74. Office of Criminal Investigations
  • 75. Omni ID
  • 76. Omnia
  • 77. Ortho biotech
  • 78. Ortho-McNeil Pharmaceuticals
  • 79. Pacific Holovisions
  • 80. Permanent Forum on International Pharmaceutical Crime (PFIPC)
  • 81. Pfizer
  • 82. PharmaSecure
  • 83. PhotoSecure
  • 84. Portalis
  • 85. PTS Intermediate Holdings LLC
  • 86. Raumedic
  • 87. Recipharm
  • 88. Rehau Group
  • 89. Robert Bosch GmbH
  • 90. Saffron Hill Ventures
  • 91. Sanofi Aventis
  • 92. Schreiner ProSecure
  • 93. SecureRF
  • 94. SecureSpin Systems
  • 95. Sekuworks
  • 96. Siemens
  • 97. SKAI Ventures
  • 98. Smartrac
  • 99. Sproxil
  • 100. Stealth Co. Inc
  • 101. Stealth Mark
  • 102. Tagsys
  • 103. Themis Medicare
  • 104. Thermo Scientific
  • 105. TopFlight Corporation
  • 106. Total Brand Security
  • 107. TraceLink Inc
  • 108. TruTag Technologies
  • 109. United States Food and Drug Administration
  • 110. Universal Postal Union
  • 111. Universal Corporation Limited
  • 112. UPM Raflatac
  • 113. Verify Brands
  • 114. Videojet
  • 115. ViiV Healthcare
  • 116. Vordata
  • 117. Wave-Logic
  • 118. WaveTrend
  • 119. Wellness Center USA Inc
  • 120. Wendell Smith
  • 121. World Customs Organisations
  • 122. World Health Organisation
  • 123. WuXiPharmaTech
  • 124. Xerafy
  • 125. Zebra Technologies
Back to Top